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Abstract
Background: Drug resistance is a significant problem in the treatment of ovarian cancer and can be caused by
multiple mechanisms. Inhibition of apoptosis by the inhibitor of apoptosis proteins (IAPs) represents one such
mechanism, and can be overcome by a mitochondrial protein called second mitochondria-derived activator of
caspases (SMAC). We have previously shown that the ligands of sigma-2 receptors effectively induce tumor cell
death. Additionally, because sigma-2 receptors are preferentially expressed in tumor cells, their ligands provide an
effective mechanism for selective anti-cancer therapy.
Methods: In the current work, we have improved upon the previously described sigma-2 ligand SW43 by conjugating
it to a pro-apoptotic small molecule SMAC mimetic SW IV-52, thus generating the novel cancer therapeutic SW IV-134.
The new cancer drug was tested for receptor selectivity and tumor cell killing activity in vitro and in vivo.
Results: We have shown that SW IV-134 retained adequate sigma-2 receptor binding affinity in the context of the
conjugate and potently induced cell death in ovarian cancer cells. The cell death induced by SW IV-134 was significantly
greater than that observed with either SW43 or SW IV-52 alone and in combination. Furthermore, the intraperitoneal
administration of SW IV-134 significantly reduced tumor burden and improved overall survival in a mouse xenograft
model of ovarian cancer without causing significant adverse effects to normal tissues. Mechanistically, SW IV-134
induced degradation of cIAP-1 and cIAP-2 leading to NF-қB activation and TNFα-dependent cell death.
Conclusions: Our findings suggest that coupling sigma-2 ligands to SMAC peptidomimetics enhances their
effectiveness while maintaining the cancer selectivity. This encouraging proof-of-principle preclinical study supports
further development of tumor-targeted small peptide mimetics via ligands to the sigma-2 receptor for future
clinical applications.
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Background
Ovarian cancer is the second most common gynecologic
malignancy in the United States. However, it is the dead-
liest of all gynecologic cancers; of the 28,080 expected
deaths from gynecologic malignancies annually, about
50% or 14,030 will be from ovarian cancer [1]. Most pa-
tients respond well to the initial treatment with surgical
de-bulking and combination chemotherapy [2]. The dis-
ease eventually recurs in a large number of patients lead-
ing to death mainly due to the lack of effective treatments
against drug resistant disease [3]. There is a clear need to
identify novel therapeutic agents that target critical drug
resistance pathways to improve survival in ovarian cancer.
Apoptosis or programmed cell death is a cell suicide
mechanism which plays a critical role in the development
and homeostasis in vertebrates and invertebrates [4].
Inhibition of apoptosis can prevent cancer cell death and
promote the development of drug resistance in various ma-
lignancies [5]. The inhibitor of apoptosis proteins (IAPs)
are among the principal molecules that contribute to this
phenomenon [6]. The anti-apoptotic activity of IAPs can be
overcome by second mitochondria-derived activator of cas-
pases (SMAC), a mitochondrial protein which is released
into the cytoplasm in response to apoptotic stimuli [7]. A
number of compounds that mimic the function of the
SMAC proteins have been described recently with striking
pro-apoptotic activity reported in vitro and in vivo [8-11].
We have previously described the development and po-
tential diagnostic and therapeutic application of sigma-2
ligands for various types of malignancies [12-15], and
shown that sigma-2 receptor ligands bind to the PGRMC1
protein complex [16]. Sigma-2 ligands are especially suit-
able for purposes of diagnostic imaging and therapeutic
targeting of solid tumors due to their high selectivity for
tumor cells in vivo [17,18]. Furthermore, by virtue of their
rapid internalization and binding to the sigma-2 receptor
[19], these ligands represent excellent candidates for se-
lective delivery of anticancer drugs into the tumor cells
[14]. Taking advantage of these two unique properties of
sigma-2 ligands, we have generated dual-domain thera-
peutics, wherein sigma-2 ligands additionally function as
targeting domains for a cancer-selective delivery of ef-
fector molecules such as pro-apoptotic peptides into the
tumor cells (12). One such compound is SW IV-134,
which is a conjugate of the sigma-2 ligand SW43 and a
small molecule SMAC mimetic SW IV-52. In our current
report, we describe in detail the in vitro characterization
of SW IV-134 and explore its effectiveness in preclinical
models of ovarian cancer.
Results
The novel sigma-2/SMAC drug conjugate SW IV-134
In continuation of our work on the cancer-selective de-
livery of drug cargoes via the sigma-2 delivery platform,
we extended our efforts from peptides to peptidomi-
metics. One of the key modulators of drug resistance in
many types of human malignancies is intracellular XIAP.
We built on the previously described small molecule
XIAP-inhibitor, SMAC, derived from the endogenous in-
hibitor of the intrinsic apoptosis pathway [20]. The SMAC
peptidomimetic SW IV-52 exactly matches the published
structure of this small molecule XIAP-inhibitor [20], and
was chemically linked to the sigma-2 receptor selective
ligand SW43 (see M&M for details on drug synthesis),
giving rise to the novel drug conjugate SW IV-134
(Figure 1A). Based on the parental compounds, this new
cancer drug was predicted to selectively find its target (via
its delivery moiety SW43) and enhance SW43 induced
apoptosis according to the activity profile of its cargo (SW
IV-52). The structural features of the delivery vehicle and
the drug cargo were well preserved in the chemically com-
bined cancer therapeutic SW IV-134 (Figure 1A).
In order to verify its unaltered target recognition prop-
erties, the binding affinity of SW IV-134 to the sigma-2
receptor was determined using previously established
methods employing rat liver membrane homogenates
(see M&M and Ref [19] for details on receptor binding
determinations). SW IV-134 exhibited an excellent
sigma-2 receptor binding profile (Ki sigma-2: 22.6 ± 1.8
nM), which was comparable to that of the parental mol-
ecule SW43 (Ki sigma-2: 7.1 ± 1.3 nM) (Additional file 1:
Table S1). As another means to probe for the ability of
SW IV-134 to bind to the sigma-2 receptor, we per-
formed a competition assay using intact ovarian cancer
cells and the fluorescently labeled SW43 homolog
SW120 [21]. Pretreatment of the ovarian cancer cell line
SKOV3 with SW IV-134 resulted in a dose-dependent re-
duction of SW120 signal intensity and was completely
blocked with the highest concentration of SW IV-134 used
in this assay system (Figure 1B). Of note, a similar effect
was seen with SW43 alone, while SW IV-52 (the SMAC
peptidomimetic) was nearly incapable of blocking the up-
take of SW120 (Additional file 2: Figure S1). Together,
these data support the notion that the receptor binding
properties of the sigma-2 ligand SW43 were not altered
following conjugation to the SMAC mimetic SW IV-52.
SW IV-134 enhances cancer cell death
We tested the killing activity of SW43, SW IV-52, a
combination of individual components of SW43 and SW
IV-52, and the chemically linked conjugate SW IV-134,
in a panel of four ovarian cancer cell lines. Although
SW43 was effective against different ovarian cancer cell
lines, SW IV-52 had minimal single-agent activity at
concentrations up to 200 μM (Figure 2). Even though we
noticed an augmentation of cell death with the combin-
ation of SW43 and SW IV-52, greater cytotoxicity was
induced upon treatment with the chemically linked
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conjugate, SW IV-134 (Figure 2, p < 0.03 for all cell lines
except OVCAR3, NS).
We have previously shown that at higher concentra-
tions, sigma-2 ligands cause cancer cell death by multiple
pathways, involving caspase activation and lysosomal
destabilization [13,15,22]. Herein, we demonstrate that
SW IV-134 induces apoptotic cell death at substantially
lower concentrations than the unconjugated sigma-2 lig-
and. Along these lines, activation of caspase 3, caspase 8,
and caspase 9 was induced by SW IV-134, but not by
SW43 in different ovarian cancer cell lines (Figure 3A,
and Additional file 3: Figure S2). These caspases are well
known to be the initiators and executioners of apoptotic
signals generated from diverse types of stimuli [23]. An-
other means to investigate programmed cell death is mon-
itoring the inversion of phosphatidylserine at the plasma
membrane, which is one of the hallmarks of the early
stages of apoptosis, and can be detected by cell surface
binding of Annexin V [24]. Treatment with SW IV-134
in SKOV3 cells increased Annexin V binding relative to
the untreated control cells in a dose dependent manner
(Additional file 4: Figure S3). Additionally, SW IV-134
induced cell death was significantly reduced with the
pan-caspase inhibitor Z-VAD-FMK, further pointing to
the induction of apoptosis by a caspase-dependent mecha-
nism (Figure 3B, p < 0.018).
SW IV-134 leads to degradation of cIAP-1, cIAP-2, and
activation of NF-қB
SMAC mimetics negatively regulate the caspase-inhibiting
activity of IAPs [7,25]. In order to study the mechanism of
SW IV-134 mediated cancer cell death, we examined its
effect on IAP proteins in various ovarian cancer cell lines.
Treatment with SW IV-134 led to a rapid loss of both
cIAP-1 and cIAP-2 without affecting the XIAP levels
(Figure 4A, and Additional file 5: Figure S4). It has been
reported that cIAP-1 and cIAP-2 function as E3 ligases,
responsible for the proteasomal degradation of NF-қB-in-
ducing kinase (NIK) [26]. Under this premise, SW IV-134
mediated degradation of cIAP1 and cIAP2 would prevent
the proteasomal degradation of NIK. Indeed, treatment with
SW IV-134 resulted in the accumulation of NIK (Figure 4A),
which was not seen with SW43 or vehicle treated cells.
Additionally, treatment with SW IV-134 led to activation
(phosphorylation) of NF-қB (p65) (Figure 4A). Taken
together, these data suggest that SW IV-134 stimulated
A
B
Figure 1 Compound structures and cell binding characteristics of SW IV-134. (A) The chemical structures of sigma-2 ligand SW43, the SMAC
peptidomimetic SW IV-52, and the chemical conjugate SW IV-134. Note that the chirality of SW IV-52 is fully retained in the drug conjugate (asterisks).
(B) SW IV-134 prevents uptake of the fluorescently labeled sigma-2 ligand SW120 in a dose-dependent fashion. SKOV3 cells were pretreated with
increasing concentration of SW IV-134, followed by incubation with SW120, prior to analysis by flow cytometry.
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Figure 2 Conjugation of the SMAC mimetic SW IV-52 to SW43 significantly enhances the killing potential of the individual components.
(A) SKOV3, (B) OVCAR3 (C) HEY A8 and (D) HEY A8 MDR cells were treated with increasing doses of SW43, SW IV-52, SW43 plus SW IV-52, and SW IV-134
for 18 hours. Cell viability was determined by CellTiter-Glo assays [p < 0.015 (A), NS (B), p < 0.017 (C), p < 0.034 (D), one-way ANOVA].
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activation of NF-қB signaling, does not require loss of
XIAP, but rather relies on the proteasomal degradation of
cIAP-1 and cIAP-2. To further support this hypothesis, SW
IV-134 mediated cell death was significantly reduced in the
presence of the proteasome inhibitor MG132 (Figure 4B,
p < 0.011).
SW IV-134 induces TNFα-dependent cell death
Next, we examined the effect of SW IV-134 on the pro-
duction of TNFα, a well-established target of NF-қB sig-
naling [8]. Treatment with SW IV-134 resulted in a 20-50
fold increase in TNFα mRNA levels compared to the un-
treated cells (Figure 5A, p < 0.0001). The induction of
TNFα mRNA was maximal at 24 hours post-treatment. We
also evaluated the effect of SW IV-134 on TNFα protein
secretion. SKOV3 cells were treated with SW IV-134, and
conditioned medium was harvested at 4, 12, and 24 hours
post treatment and analyzed by ELISA. TNFα was un-
detectable at 4 hours, mildly elevated at 12 hours, and
highest levels were seen at the 24 hour time point, consist-
ent with its transcriptional upregulation (Figure 5B, p <
0.0001). To investigate the functional importance of TNFα
protein secretion, we treated SKOV3 cells with SW IV-
134, either alone or in the presence of TNFα-blocking
antibody. TNFα-blocking antibody provided significant
protection from cell death induced by SW IV-134, which
suggests that the pro-apoptotic activity of SW IV-134 is













Figure 3 Treatment with SW IV-134 results in caspase-mediated
cell death. (A) Cells were treated with vehicle only (Ctrl.), SW43
(10 μM), and SW IV-134 (10 μM) for 24 hours. Cell lysates were
subjected to Western blot analysis, and probed with antibodies
specific for the precursors and activated forms of caspases 8, 9, and
3. (B) SKOV3 cells were treated with SW IV-134 at indicated doses
either alone or in the presence of the pan-caspase inhibitor Z-VAD-
FMK (20 μM) for 18 hours. Cell viability was determined by CellTiter-










Figure 4 SW IV-134 engages in SMAC-dependent pathway
activation. (A) SKOV3 cells were treated with vehicle only (Ctrl.),
SW43 (10 μM), and SW IV-134 (10 μM) for 4 hours and cell lysates
were subjected to Western blot analysis using antibodies against
XIAP, cIAP-1, cIAP-2, NF-қB and NIK. While XIAP seems unaffected
under the conditions used, cIAP-1 and cIAP-2 proteins are readily
undetectable shortly post treatment. SW IV-134 treatment also leads
to accumulation of NF-қB inducing kinase (NIK) and activation of
NF-қB pathway. (B) SKOV3 cells were treated with SW IV-134 at the
indicated doses either alone or in the presence of proteasome
inhibitor MG132 (20 μM) for 18 hours. Cell death induction is partially
rescued by MG132 and suggests a requirement for an intact proteasomal
machinery to achieve efficient tumor cell killing. Cell viability was
determined as described in the experimental methods (p < 0.011,
Student’s t-test).
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In vivo efficacy of SW IV-134 in an intraperitoneal
xenograft model of ovarian cancer
The response of intraperitoneal SKOV3-Luc xenografts
to treatment with SW43, SW IV-134, or vehicle-control
was assessed by bioluminescence imaging. Tumor re-
gression was evident by the end of the first week of
treatment with SW IV-134 (Figure 6A, p < 0.0097). In






Figure 5 SW IV-134 induces activation of the TNFα-dependent extrinsic death pathway. (A) Quantitative real-time PCR analysis of TNFα
mRNA expression was done on RNA samples derived from SKOV3 cells treated with SW IV-134 (1 μM and 3 μM) for indicated time periods. All values
were normalized to a GAPDH internal control (p < 0.0001, one-way ANOVA). (B) SKOV3 cells were treated with SW IV-134 (1 μM and 3 μM) and cell-
culture supernatants were collected at 4, 12, and 24 hours after treatment, and subsequently examined by anti-TNFα ELISA according to manufacturer’s
instructions (p < 0.0001, one-way ANOVA). (C) SKOV3 cells were treated with SW IV-134 at indicated doses either alone or in the presence of anti-TNFα
blocking antibody for 18 hours. Cell viability was determined as described in the experimental methods (p < 0.019, Student’s t-test).


































Figure 6 SW IV-134 is a potent single-agent cancer drug in a peritoneal mouse xenograft model of ovarian cancer. (A) Female SCID
mice were inoculated intraperitoneally with 5 × 106 SKOV3-Luc cells. Treatment was initiated with intraperitoneal injections of SW43, SW IV-134,
or vehicle control 7 days after tumor cell inoculation, and continued for a total of 3 weeks. Mice were imaged once a week during the treatment
period. Change in bioluminescence photon flux during treatment in each experimental arm (n = 15) was evaluated. Bioluminescent signals at
each time point were averaged per treatment group (mean ± SEM). Significant differences were noted between vehicle vs. SW IV-134 and SW43
vs. SW IV-134 (p < 0.0097, one-way ANOVA). (B) Bioluminescent images at the end of the treatment (day 21) of one representative mouse per
treatment arm (n = 15). Image intensity is displayed as radiance (photons/s/cm2/sr). (C) Kaplan-Meier survival analysis. At the end of the 3 week
treatment, 5 mice from each experimental group were subjected to necropsy. The remaining 10 mice from each treatment group were followed
until death to examine overall survival (p < 0.0108, Log-rank test).
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and the vehicle-only treatment groups. At the end of the
3 week treatment, the signal intensity in the SW IV-134
treatment group was significantly lower than both the
SW43 and the vehicle-only treatment groups (Figure 6B).
SW IV-134 treatment also conferred a survival advantage
for mice in this experiment. The median survival for mice
treated with SW IV-134 was 86.5 days compared to
76.5 days for mice treated with SW43 and 74 days for
those treated with the vehicle only (Figure 6C, p < 0.0108).
We also assessed the potential of our drug conjugate
SW IV-134 to cause adverse effects following intraperi-
toneal administration. The primary finding was mild to
moderate peritonitis which was also seen in the SW43
and the vehicle treated mice, suggesting it to be vehicle
related phenomenon. In addition, the mice treated with
SW IV-134 exhibited slightly lower hemoglobin levels
and higher total white blood cell count than the SW43
and the vehicle treated mice (Additional file 6: Table S2).
The gross pathology and histology reports of various in-
ternal organs were not appreciably different between the
SW IV-134, SW43, and the vehicle-only groups. The
only exception was the presence of mild splenomegaly in
SW IV-134 treated mice, which is likely due to compensa-
tory extra-medullary hematopoiesis. Similarly, there was
no significant difference between the treatment groups
with regard to the comprehensive blood chemistry panel
also performed at the time of necropsy (Additional file 6:
Table S2). Throughout the course of the treatment, mice
in all three treatment groups appeared well, and did not
experience any treatment related deaths.
Discussion
Sigma-2 receptors are preferentially expressed in prolif-
erating tumor cells [27], and are therefore considered
potential targets for a selective delivery of therapeutics
into the cancer cells. Insights from the current under-
standing of the cell death pathways have led to the iden-
tification of several candidate proteins that could be
targeted for the eradication of cancer cells. One such
class of prominent cell survival factors are the inhibitors
of apoptosis proteins (IAPs). IAPs are frequently overex-
pressed in many types of human malignancies, making
them attractive targets for therapeutic intervention [28].
In the current work we have shown the feasibility of
conjugating a small molecule SMAC mimetic to a
sigma-2 ligand and demonstrated the effectiveness of the
conjugate in treatment of ovarian cancer using in vitro
and in vivo studies.
Our results indicate that SW IV-134 potentiates the
sigma-2 ligand related cell death in different ovarian
cancer cell lines (Figure 2). Furthermore, the cell death
induced by SW IV-134 was significantly greater than
that observed with a combination of SW43 and SW IV-
52 (Figure 2). This is likely due to the more efficient
delivery of the small molecule SMAC mimetic into the
tumor cells following conjugation to the sigma-2 ligand
SW43. The SMAC mimetic in turn enhances the cyto-
toxicity of the compound by negating the activity of two
anti-apoptotic proteins, cIAP-1 and cIAP-2 (Figure 4A),
thus establishing an intracellular environment that is
conducive for NF-қB activation. The loss of cIAPs with
SW IV-134 treatment is likely secondary to the SMAC
mimetic-induced auto-ubiquitination and proteasomal deg-
radation, and has been shown by others [29].
The NF-қB transcription factors [such as NF-қB1 (p105/
p50), NF-қB2 (p100/p52), RelA(p65), ReLB, and c-ReL]
are usually retained in the cytoplasm of un-stimulated cells
by IқB (Inhibitor of қB) proteins [30]. In the canonical NF-
қB pathway, phosphorylation of IқB by IKK2 (IқB Kinase)
leads to its proteasomal degradation, allowing nuclear trans-
location of the transcription factors [31,32]. It has been
shown that phosphorylation of NF-қB p65 is critical for the
canonical NF-қB signaling [33]. On the other hand, NF-қB-
inducing-kinase (NIK) is one of the key regulators of the
non-canonical NF-қB pathway. NIK phosphorylates IKKα,
resulting in the phosphorylation of p100, which leads to the
ubiquitination and partial proteasomal degradation of p100
to its mature p52 form [34,35]. Treatment with SW IV-134
led to phosphorylation of NF-қB p65 as well as accumula-
tion of NIK (Figure 4A), suggesting its role in activation of
both canonical and non-canonical NF-қB signaling path-
ways. The activation of NF-қB pathways, in turn, led to the
transcriptional upregulation of TNFα mRNA (Figure 5A),
directly corresponding with an increase in TNFα protein
(Figure 5B) and subsequent potentiation of cell death via ac-
tivation of the extrinsic pathway of apoptosis, similar to
what has been described by other investigators [26].
SW IV-134 reduced the tumor burden of the intraperi-
toneal xenografts and significantly improved survival in
mice (Figure 6). A frequent criticism of many xenograft
models is the location of tumor formation and its resem-
blance to human disease [36]. Because most ovarian can-
cers in humans are diagnosed at late stages, we believe
that our intraperitoneal tumor model resembles more
closely the advanced-stage human disease than a local-
ized orthotopic model. In this widely metastatic intra-
peritoneal model, SW IV-134 demonstrated modest
effectiveness, extending median survival by 10 days. Fur-
thermore, the treatment was well tolerated with minimal
adverse effects on the animals as evidenced by blood
testing and histopathological analysis of various organs
and tissues harvested at the end of treatment. Treatment
with sigma-2 ligands has repeatedly been shown to induce
apoptosis with limited off-site toxicities. This is because
cancer selectivity is a key feature of our sigma-2 based
platform concept, and has been demonstrated in numer-
ous previous studies [12,15,19,21]. In one of these studies
it was demonstrated that nude mice bearing either mouse
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66 (mammary carcinoma) or MDA-MB-435 cells (human
melanoma) injected with the fluorescently-labeled sigma-2
ligand SW120 was taken up selectively by proliferating
tumor cells and not by the generally quiescent peripheral
blood mononuclear cells [21]. Similar results were seen
in vitro, where sigma-2 ligands were preferentially taken
up by transformed cancer cells and not by the immortal-
ized normal human HPDE cells (data not shown). Fur-
thermore, new clinical data have recently become
available that once again highlight the tendency of our
drugs to localize primarily to solid tumors with negligible
accumulation in the surrounding, healthy tissue [37].
These results suggest that SW IV-134 may have consider-
able potential for the treatment of ovarian cancers with a
favorable therapeutic window.
Anti-tumor efficacy of SMAC mimetics has been re-
ported in a variety of tumor-types by other investigators
[20,38]. Furthermore, SMAC mimetics have been shown
to exhibit considerable synergism in combination with a
wide variety of therapeutic agents ranging from conven-
tional therapy to TRAIL and other biologic agents
[9-11,39]. Because SW IV-134 induced apoptosis targets
the same mechanistic pathways as the SMAC mimetics,
it can also be potentially combined with different che-
motherapeutic agents to overcome resistance to therapy-
induced apoptosis. We believe that the selective delivery
of SMAC mimetics into the tumor cells by sigma-2 li-
gands (as achieved with SW IV-134) will likely enhance
its on-target effects while keeping the off-target effects
to a minimum. We thus envision the unique properties
of SW IV-134 highly advantageous when used alone but
especially in combination with existing and/or novel
chemotherapeutics. As a result, we are currently in the
process of exploring the tumoricidal effects of SW IV-
134 in combination with different chemotherapeutic
agents, to identify the most efficacious treatment regi-
men which could be moved forward for further clinical
investigations.
Conclusions
In summary, we have described the effectiveness and po-
tential application of SW IV-134, a novel conjugate of
sigma-2 ligand and a small molecule SMAC peptidomi-
metic, in the treatment of ovarian cancer. We believe
this approach is particularly meritorious considering the
cancer selectivity of sigma-2 ligands and the important
contribution of IAPs to both de-novo and acquired
treatment resistance, and therefore deserves serious con-
sideration for future clinical development.
Materials and methods
Cell lines and reagents
SKOV3 cells were obtained from Dr. Robert Mach
(Washington University School of Medicine, St. Louis,
MO), Hey A8 and Hey A8 MDR cells from Dr. Anil
Sood [40] (M.D. Anderson Cancer Center, Houston,
TX), and OVCAR3 cells were purchased from American
Type Culture Collection (ATCC, Manassas, VA). SKOV3
cells were labeled with a eYFP/luciferase reporter fusion
protein by retroviral infection to generate SKOV3-Luc
cells (G. Garg and D. Spitzer, unpublished data). Protein
expression was confirmed by flow cytometry and
in vitro luciferin conversion. SW43 [19] and SW IV-52
[41] were synthesized as previously reported. Synthesis
of SW IV-134 is described in detail in the Additional
file 7: Supplementary methods. MG-132 was purchased
from Calbiochem (Billerica, MA), Z-VAD-FMK from Enzo
Life Sciences (Ann Arbor, MI), and anti-TNFα antibody
was purchased from R&D systems (Minneapolis, MN).
Receptor binding assays
The sigma-1 and sigma-2 receptor binding affinities of
SW IV-134 were determined as previously described
[42]. Briefly, guinea pig brain (sigma-1 assay) or rat liver
(sigma-2 assay) membrane homogenates (~300 μg pro-
tein) were diluted with 50 mM Tris-HCl, pH 8.0 and incu-
bated with the radioligand {~5 nM [3H](+)-pentazocine
(34.9 Ci/mmol; sigma-1 assay) or ~5 nM [3H](+)-DTG
(58.1 Ci/mmol; sigma-2 assay)} and SW IV-134 with con-
centrations ranging from 0.1 nM to 10 μM in a total vol-
ume of 150 μL in 96-well plates at 25°C. After incubating
for 120 minutes, the reactions were terminated by the
addition of 150 μL of ice-cold wash buffer (10 mM Tris-
HCl, 150 mM NaCl, pH 7.4) using a 96-channel transfer
pipette (Fisher Scientific, Pittsburg, PA), and the samples
harvested and filtered rapidly into a 96-well fiberglass fil-
ter plate (Millipore, Billerica, MA) that had been pre-
soaked with 100 μL of 50 mM Tris-HCl, pH 8.0 for
1 hour. Each filter was washed three times with 200 μL of
ice-cold wash buffer, and the bound radioactivity quanti-
fied using a Wallac 1450 MicroBeta liquid scintillation
counter (Perkin Elmer, Boston, MA). Nonspecific binding
was determined in the presence of 10 μM cold haloperidol.
Blocking studies
SKOV3 cells (3 × 104/well) were seeded into 6 cm plates
for 24 hours before treatment. The cells were incubated
with 5, 10, 50, and 100 μM doses of SW IV-134 for
30 minutes at 37°C. After this step, 10 nM SW120 was
added to the cell culture medium containing SW IV-
134. After 30 minute incubation at 37°C, cells were
washed twice with phosphate buffered saline (PBS) and
harvested with 0.05% trypsin EDTA (Life Technologies,
Grand Island, NY). The cells were centrifuged at 1000 ×
g for 5 minutes and pellets washed twice with PBS. In-
ternalization of SW120 was determined by flow cyt-
ometer (FACSCalibur, BD Biosciences, San Jose, CA).
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Annexin V binding
SKOV3 cells were treated with different concentrations
of SW IV-134 (3 μM, 6 μM, and 10 μM) for 16 hours.
Staining was performed using the Annexin V Apoptosis
Detection Kit (BioLegend, San Diego, CA) according to
the manufacturer’s instructions. The apoptosis rate was
determined by flow cytometry (FACSCalibur, BD Biosci-
ences, San Jose, CA).
Western blot analysis
Cells were lysed in radioimmunoprecipitation assay buf-
fer [50 mM Tris, 150 mM sodium chloride, 1.0 mM
EDTA, 1% Nonidet P40, and 0.25% SDS (pH 7.0)], sup-
plemented with complete protease inhibitor cocktail
(Roche, Mannheim) and phosphatase inhibitor cocktail 1
(Sigma Chemical Co., St. Louis, MO). The protein con-
centration was determined using a BioRad Dc protein
assay kit (Bio-Rad Laboratories, Hercules, CA). Lysates
containing 30 μg of protein were run on a 12% poly-
acrylamide gel and transferred to a PVDF membrane
(Bio-Rad Laboratories, Hercules, CA). The PVDF mem-
brane was incubated with 5% nonfat dry milk for 1 h at
room temperature, then overnight with a primary anti-
body at 4°C, and finally with the secondary antibody,
horse-radish peroxidase-conjugated IgG, and signal visu-
alized using the super Signal West Pico Chemiluminis-
cent Substrate assay kit (Pierce Biotechnology, Rockford,
IL). The primary antibodies against cIAP1, cIAP2, XIAP,
NIK, NF-Қb (p65), phospho- NF-қB (p65), caspase3, cas-
pase 8, and caspase 9 (all caspase-detecting antibodies
react with both their precursors and cleaved [activated]
forms) were purchased from Cell Signalling Technology
(Danvers, MA, USA), whereas actin antibody was from
Santa Cruz Biotechnology (Dallas, TX). The secondary
antibodies against mouse, rabbit, and goat were also pur-
chased from Santa Cruz Biotechnology (Dallas, TX).
Quantitative RT-PCR
SKOV3 cells were treated with SW IV-134 (1 μM, 3 μM)
or vehicle-control for 4 hours, 12 hours, and 24 hours.
At the end of each treatment, cells were harvested and
total RNA was isolated using TRIzol reagent (Invitrogen,
Grand Island, NY) and RT-PCR performed as per the
protocol described before [43]. Briefly, one microgram of
RNA from each sample was reverse transcribed to
cDNA with Retroscript (Ambion, Austin, TX). Resulting
cDNA was diluted to an equivalent of 10 ng/μL of input
RNA. Primer/probe sets for TNFα and GAPDH were
purchased from Applied Biosystems (Grand Island, NY).
Each reaction consisted cDNA, TaqMan Master Mix
(Applied Biosystems), and primer/probe set in a total of
10 μL, following the manufacturer’s standard protocol.
For each transcript/sample, triplicate reactions were
done in an ABI7500FAST Sequence Detection System.
TNFα data were normalized for expression with GAPDH,
and results were expressed as fold change over untreated
controls.
ELISA
SKOV3 cells were treated with SW IV-134 (1 μM and
3 μM). Cell culture supernatants were collected at 4, 12,
and 24 hours after treatment. Medium was collected,
floating cells were removed by centrifugation at 1200 × g
for 5 minutes, and samples were frozen at -20°C until ana-
lysis. TNFα ELISA was performed using a quantitative
high sensitivity sandwich immunoassay from eBioscience
(San Diego, CA) as per the manufacturer’s instructions.
Analysis of cell death
Cells (1 × 104) were seeded into 96 well plates. Treat-
ment as described in the figure legends was initiated the
following day. Cell viability was determined 18 hours
after treatment using CellTiter-Glo Luminiscent Viabil-
ity Assay (Promega, Madison, WI). Data were recorded
with a SpectraMax Gemini microplate spectrofluorome-
ter, Molecular Devices (Silicon Valley, CA).
Caspase activation assays
Caspase 3, 8 and 9 activities were measured using
Caspase-Glo® Assay Systems according to the manufac-
turer’s instructions (Promega, Madison, WI). Briefly, the
assay systems are based on caspase-specific substrates,
which are activated by cleavage, resulting in caspase spe-
cific luminescence signals. HeyA8 cells were plated at a
density of 1 × 104 in white 96 well, clear bottom plates
for 24 hours before treatment. Cells were treated with
different concentrations of SW IV-134. Caspase 3, 8 and
9 assays were performed by adding 100 μl of caspase re-
agents to each well. The contents were mixed using a
plate shaker for 30 seconds and incubated at room
temperature for 90 minutes. Luminescence signal was
measured using a multi-mode microplate reader (Bio-
Tek, Winooski, VT).
Animal studies
All studies were performed in accordance with an animal
protocol approved by the Washington University Institu-
tional Animal Care Facility. Female severe combined im-
munodeficient mice (SCID) were purchased from Taconic
Farms (Hudson, NY) at age 6 weeks. SKOV3-Luc cells
(5 × 106) were inoculated intraperitoneally and mice were
randomized 7 days later into one of the three treatment
groups according to their baseline luciferase activity em-
ploying bioluminescence imaging (BLI). For biolumines-
cence imaging, mice were injected intraperitoneally with
150 μg/g D-luciferin (Biosynth, Naperville, IL) in PBS, anes-
thetized with 2.5% isoflurane, and imaged with a charge-
coupled device (CCD) camera-based bioluminescence
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imaging system (IVIS 100; Caliper, Hopkinton, MA; expos-
ure time 300 seconds, binning 16, field of view 12, f/stop 1,
open filter). Signal was displayed as radiance (photons/sec/
cm2/sr) [44].
In vivo experiments were conducted with 15 mice per
treatment group. Treatment involved daily intraperito-
neal injections with 90 μL of SW43 (7.5 mM stock), SW
IV-134 (7.5 mM stock), or vehicle-only (25% cremophor
in H2O) for 3 weeks. Tumor burden was monitored by
bioluminescence imaging once a week during the treat-
ment period. At the end of the treatment, 5 mice were
randomly removed per treatment group and submitted
for necropsy to the Washington University Department
of Comparative Medicine. Blood samples were collected
by intracardiac withdrawal prior to necropsy for chemis-
try and hematology work-up. In addition, various key or-
gans were harvested for gross and histopathological
examination. The remaining 10 mice from each treat-
ment group were followed over time to examine overall
survival. For survival studies, actual death or poor phys-
ical condition/large tumor size meeting criteria for eu-
thanasia, constituted a death event.
Statistical analyses
Statistical analyses and data plotting were performed
using GraphPad Prism software version 5 (San Diego,
CA). Results were expressed as mean ± SEM of at least 3
biological replicates. One-way ANOVA was used to
analyze the differences in cell killing assays (Titer-Glow),
TNFα quantification assays (RT-PCR and ELISA) and
for measuring tumor sizes. The Kaplan-Meier survival
curve was plotted and the difference between the groups
was compared with a Log-rank test. P values < 0.05 were
considered significant for all analyses.
Additional files
Additional file 1: Table S1. Binding Affinities for Sigma-1 and Sigma-2
Receptors. The sigma-1 and sigma-2 receptor binding affinities of SW IV-134
were determined as previously described [43]. For details see also the
Materials and methods section.
Additional file 2: Figure S1. Receptor binding characteristics of the
individual components of SW IV-134. SKOV3 cells were pretreated with
increasing concentration of (A) SW43 and (B) SW IV-52, followed by incubation
with SW120, prior to analysis by flow cytometry. SW43 prevents uptake of the
fluorescently labeled sigma-2 ligand SW120 in a dose-dependent fashion,
similar to the drug conjugate SW IV-134, while the SMAC mimetic SW IV-52 is
nearly incapable of interfering with the uptake of SW120.
Additional file 3: Figure S2. SW IV-134 induces caspase activation in
ovarian cancer. Caspase 3, 8 and 9 activities were measured in Hey A8
cells using Caspase-Glo® Assay Systems (Promega). Hey A8 cells were
treated with SW IV-134 at indicated drug concentrations for 24 hours.
Caspase assays were performed by adding 100 μl lysis buffer containing
the substrates for the respective caspase to be assayed. Luminescence
signal intensities were recorded using a multi-mode microplate reader
(BioTek). Compared to untreated controls (DMSO), cells treated with SW
IV-134 responded with significant increases in caspase activities,
presented as fold over DMSO control. (A) caspase 8; (B) caspase 9; and
(C) caspase 3. p < 0.001 for all analyses, one-way ANOVA.
Additional file 4: Figure S3. Flow cytometric determination of
apoptosis. SKOV3 cells were treated with increasing concentrations of SW
IV-134. Untreated cells served as a negative staining control. The cells
were then assessed for apoptosis induction by flow cytometry following
staining with propidium iodide/Annexin V.
Additional file 5: Figure S4. SW IV-134 leads to rapid degradation of
cIAP-1 in several ovarian cancer cell lines. SKOV3, Hey A8, and Hey A8
MDR cells were treated with vehicle only (Ctrl.), SW43 (10 μM), and SW
IV-134 (10 μM) for 2 hours. Cell lysates were prepared and subjected to
Western blot analysis using an antibody against cIAP-1, which becomes
readily undetectable shortly after treatment. The same membrane was
also probed for β-Actin to demonstrate equal protein loading.
Additional file 6: Table S2. Complete blood count and serum
chemistries for severe combined immunodeficient (SCID) mice treated
with SW IV-134, SW43, and vehicle control. SCID mice were treated daily
with intra-peritoneal injections of SW IV-134, SW43, and vehicle control
for 3 weeks. At the end of treatment, blood was collected from mice in
each treatment group and analyzed for hemoglobin, white blood count,
and platelets. Serum chemistries were also obtained to determine the
levels of liver enzymes aspartate aminotransferase (AST) and alanine
aminotransferase (ALT), renally cleared metabolites blood urea nitrogen
(BUN) and creatinine, as well as total protein and glucose. The mice
treated with SW134 were noted to have a statistically significant decrease
in hemoglobin and an increase in white blood count compared to those
treated with SW43 or vehicle control.
Additional file 7: Supplementary methods.
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